S

SCHOTT Pharma AG & Co KgaA
XETRA:1SXP

Watchlist Manager
SCHOTT Pharma AG & Co KgaA
XETRA:1SXP
Watchlist
Price: 29.1 EUR 2.11% Market Closed
Updated: Jun 1, 2024

Profitability Summary

SCHOTT Pharma AG & Co KgaA's profitability score is hidden . We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.

Sign Up to see
Profitability Score
Sign In
Sign Up

We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.

Sign Up to see
Profitability Score
Sign In
Sign Up

Past Growth

To be successful and remain in business, both growth and profitability are important and necessary. Net Income growth is often seen as a sign of a company's efficiency from an operational standpoint, but is influenced heavily by a company's goals and challenges and should therefore be assessed in conjunction with other metrics like revenue and operating income growth.

Margins

Profit margins represent what percentage of sales has turned into profits. Simply put, the percentage figure indicates how many cents of profit the company has generated for each dollar of sale.

Profit margins help investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Earnings Waterfall
SCHOTT Pharma AG & Co KgaA

Revenue
1.1B EUR
Cost of Revenue
-730.6m EUR
Gross Profit
400.2m EUR
Operating Expenses
-167.5m EUR
Operating Income
232.7m EUR
Other Expenses
-36.4m EUR
Net Income
196.3m EUR

Margins Comparison
SCHOTT Pharma AG & Co KgaA Competitors

Country Company Market Cap Gross
Margin
Operating
Margin
Net
Margin
DE
SCHOTT Pharma AG & Co KgaA
XETRA:1SXP
4.4B EUR
35%
21%
17%
US
Thermo Fisher Scientific Inc
NYSE:TMO
216.8B USD
40%
17%
14%
US
Danaher Corp
NYSE:DHR
188.5B USD
58%
22%
18%
US
IQVIA Holdings Inc
NYSE:IQV
39.7B USD
35%
14%
9%
US
Agilent Technologies Inc
NYSE:A
38.3B USD
51%
19%
18%
CH
Lonza Group AG
SIX:LONN
35B CHF
36%
20%
10%
KR
Samsung Biologics Co Ltd
KRX:207940
52T KRW
48%
29%
23%
US
Mettler-Toledo International Inc
NYSE:MTD
29.6B USD
59%
29%
21%
IE
ICON PLC
NASDAQ:ICLR
26.7B USD
30%
13%
8%
US
West Pharmaceutical Services Inc
NYSE:WST
24.2B USD
37%
23%
19%
US
Waters Corp
NYSE:WAT
18.3B USD
60%
27%
21%
Country DE
Market Cap 4.4B EUR
Gross Margin
35%
Operating Margin
21%
Net Margin
17%
Country US
Market Cap 216.8B USD
Gross Margin
40%
Operating Margin
17%
Net Margin
14%
Country US
Market Cap 188.5B USD
Gross Margin
58%
Operating Margin
22%
Net Margin
18%
Country US
Market Cap 39.7B USD
Gross Margin
35%
Operating Margin
14%
Net Margin
9%
Country US
Market Cap 38.3B USD
Gross Margin
51%
Operating Margin
19%
Net Margin
18%
Country CH
Market Cap 35B CHF
Gross Margin
36%
Operating Margin
20%
Net Margin
10%
Country KR
Market Cap 52T KRW
Gross Margin
48%
Operating Margin
29%
Net Margin
23%
Country US
Market Cap 29.6B USD
Gross Margin
59%
Operating Margin
29%
Net Margin
21%
Country IE
Market Cap 26.7B USD
Gross Margin
30%
Operating Margin
13%
Net Margin
8%
Country US
Market Cap 24.2B USD
Gross Margin
37%
Operating Margin
23%
Net Margin
19%
Country US
Market Cap 18.3B USD
Gross Margin
60%
Operating Margin
27%
Net Margin
21%

Return on Capital

Return on capital ratios give a sense of how well a company is using its capital (equity, assets, capital employed, etc.) to generate profits (operating income, net income, etc.). In simple words, these ratios show how much income is generated for each dollar of capital invested.

Return on Capital Comparison
SCHOTT Pharma AG & Co KgaA Competitors

Country Company Market Cap ROE ROA ROCE ROIC
DE
SCHOTT Pharma AG & Co KgaA
XETRA:1SXP
4.4B EUR
27%
16%
25%
17%
US
Thermo Fisher Scientific Inc
NYSE:TMO
216.8B USD
13%
6%
9%
8%
US
Danaher Corp
NYSE:DHR
188.5B USD
16%
10%
12%
10%
US
IQVIA Holdings Inc
NYSE:IQV
39.7B USD
22%
5%
11%
9%
US
Agilent Technologies Inc
NYSE:A
38.3B USD
21%
11%
14%
14%
CH
Lonza Group AG
SIX:LONN
35B CHF
7%
4%
9%
8%
KR
Samsung Biologics Co Ltd
KRX:207940
52T KRW
9%
5%
9%
6%
US
Mettler-Toledo International Inc
NYSE:MTD
29.6B USD
-849%
23%
48%
28%
IE
ICON PLC
NASDAQ:ICLR
26.7B USD
8%
4%
8%
6%
US
West Pharmaceutical Services Inc
NYSE:WST
24.2B USD
21%
16%
22%
20%
US
Waters Corp
NYSE:WAT
18.3B USD
69%
15%
26%
20%
Country DE
Market Cap 4.4B EUR
ROE
27%
ROA
16%
ROCE
25%
ROIC
17%
Country US
Market Cap 216.8B USD
ROE
13%
ROA
6%
ROCE
9%
ROIC
8%
Country US
Market Cap 188.5B USD
ROE
16%
ROA
10%
ROCE
12%
ROIC
10%
Country US
Market Cap 39.7B USD
ROE
22%
ROA
5%
ROCE
11%
ROIC
9%
Country US
Market Cap 38.3B USD
ROE
21%
ROA
11%
ROCE
14%
ROIC
14%
Country CH
Market Cap 35B CHF
ROE
7%
ROA
4%
ROCE
9%
ROIC
8%
Country KR
Market Cap 52T KRW
ROE
9%
ROA
5%
ROCE
9%
ROIC
6%
Country US
Market Cap 29.6B USD
ROE
-849%
ROA
23%
ROCE
48%
ROIC
28%
Country IE
Market Cap 26.7B USD
ROE
8%
ROA
4%
ROCE
8%
ROIC
6%
Country US
Market Cap 24.2B USD
ROE
21%
ROA
16%
ROCE
22%
ROIC
20%
Country US
Market Cap 18.3B USD
ROE
69%
ROA
15%
ROCE
26%
ROIC
20%

Free Cash Flow

Free cash flow (FCF) is the money a company has left over after paying its operating expenses and capital expenditures. The more free cash flow a company has, the more it can allocate to dividends, paying down debt, and growth opportunities.

If a company has a decreasing free cash flow, that is not necessarily bad if the company is investing in its growth.

See Also

Discover More